# Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma

> **NCT02626962** · PHASE2 · COMPLETED · sponsor: **Grupo Español Multidisciplinar de Melanoma** · enrollment: 52 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02626962
- **Lead sponsor:** Grupo Español Multidisciplinar de Melanoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-05
- **Final completion:** 2021-07-22
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02626962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02626962, "Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02626962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*